House of Commons
As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.
PNEUMOCOCCAL DISEASE
EDM #516
Tabled 17 November 2014
2014-15 Session
That this House notes that, whilst the introduction of vaccinations has been effective in reducing levels of pneumococcal infection in children, pneumococcal infection remains a significant public health risk, particularly among other vulnerable groups, including those aged 65 and over; expresses concern that around 84,000 people are hospitalised due to pneumococcal community-acquired pneumonia in the UK every year, with around half of these cases amongst those aged 65 and over; further notes that an estimated £269 million is spent on hospitalising adults with pneumococcal community-acquired pneumonia each year, of which around £135 million relates to those aged 65 and over; welcomes the Joint Committee on Vaccination and Immunisation's intention to conduct a review of the adult vaccination programme, considering the latest evidence on the epidemiology and cost effectiveness of adult pneumococcal disease vaccination; and expresses concern that this review is intended to take six months, potentially placing more vulnerable adults at risk.

Signatures (33)

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.
In addition to the sponsors, the following Members have signed to support the motion.
There are no withdrawn signatures for this Motion